Eledon Pharmaceuticals, Inc. (ELDN)
2.70
+0.08
(+3.05%)
USD |
NASDAQ |
Sep 21, 16:00
2.65
-0.05
(-1.85%)
After-Hours: 20:00
Eledon Pharmaceuticals Enterprise Value : 162.66M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 162.66M |
| September 17, 2026 | 165.09M |
| September 16, 2026 | 166.71M |
| September 15, 2026 | 169.94M |
| September 14, 2026 | 174.80M |
| September 11, 2026 | 175.61M |
| September 10, 2026 | 175.61M |
| September 09, 2026 | 178.84M |
| September 08, 2026 | 187.74M |
| September 04, 2026 | 195.02M |
| September 03, 2026 | 187.74M |
| September 02, 2026 | 192.59M |
| September 01, 2026 | 194.21M |
| August 31, 2026 | 191.79M |
| August 28, 2026 | 209.58M |
| August 27, 2026 | 219.29M |
| August 26, 2026 | 221.72M |
| August 25, 2026 | 231.42M |
| August 24, 2026 | 226.57M |
| August 21, 2026 | 229.80M |
| August 20, 2026 | 235.47M |
| August 19, 2026 | 237.89M |
| August 18, 2026 | 243.56M |
| August 17, 2026 | 240.32M |
| August 14, 2026 | 237.08M |
| Date | Value |
|---|---|
| August 13, 2026 | 250.03M |
| August 12, 2026 | 255.69M |
| August 11, 2026 | 254.07M |
| August 10, 2026 | 248.41M |
| August 07, 2026 | 249.22M |
| August 06, 2026 | 230.61M |
| August 05, 2026 | 229.00M |
| August 04, 2026 | 233.04M |
| August 03, 2026 | 228.19M |
| July 31, 2026 | 224.14M |
| July 30, 2026 | 226.57M |
| July 29, 2026 | 218.48M |
| July 28, 2026 | 225.76M |
| July 27, 2026 | 239.51M |
| July 24, 2026 | 240.32M |
| July 23, 2026 | 253.26M |
| July 22, 2026 | 251.64M |
| July 21, 2026 | 270.25M |
| July 20, 2026 | 262.97M |
| July 17, 2026 | 279.96M |
| July 16, 2026 | 261.35M |
| July 15, 2026 | 275.91M |
| July 14, 2026 | 278.34M |
| July 13, 2026 | 262.97M |
| July 10, 2026 | 262.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 122.90B |
| Viking Therapeutics, Inc. | 2.884B |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.63M |
| Total Expenses (Quarterly) | 31.63M |
| EPS Diluted (Quarterly) | -0.2784 |
| Earnings Yield | -36.68% |
| Normalized Earnings Yield | -33.92 |